Jia Lu

Nov 21, 2024 | dx.doi.org | Jiahui Wang |Wei Liu |Jia Lu |Mengyue Zhu

Nov 21, 2024 | pubs.acs.org | Jiahui Wang |Wei Liu |Jia Lu |Mengyue Zhu

Nov 12, 2024 | pubs.rsc.org | Xinyu Cheng |Innovative Materials |Yuke Wang |Jia Lu

Regulating oxygen redox reactions in lithium-rich materials via an Al2O3-doped ZnO layer for enhanced stability and performance† Lithium-rich materials (LRM), which hold promise as high-energy-density cathodes, face challenges due to irreversible oxygen evolution. This leads to rapid capacity decay and structural instability.

Sep 16, 2024 | pubs.acs.org | Bin Hu |Jia Lu |Wei Ding |Yanhong Liu

IntroductionClick to copy section linkSection link copied!Nitric oxide (NO) is a critical messenger with important roles in both normal cellular physiology and pathology. (1) The interaction of NO with heme proteins is vital to many biological processes, including smooth muscle relaxation, vasodilation, blood clotting, nerve-signal transduction, and immune regulation.

Sep 12, 2024 | nature.com | Aileen W. Li |Jia Lu |Quinn Walker |Hajime Hiraragi |Shobha Potluri |Alexander Cheung | +6 more

Programming cell signaling during T-cell activation represents a simple strategy for improving the potency of therapeutic T-cell products. Stim-R technology (Lyell Immunopharma) is a customizable, degradable synthetic cell biomimetic that emulates physiologic, cell-like presentation of signal molecules to control T-cell activation. A breadth of Stim-R formulations with different anti-CD3/anti-CD28 (αCD3/αCD28) antibody densities and stoichiometries were screened for their effects on multiple metrics of T-cell function. We identified an optimized formulation that produced receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeted chimeric antigen receptor (CAR) T cells with enhanced persistence and polyfunctionality in vitro, as assessed in repeat-stimulation assays, compared with a benchmark product generated using a conventional T-cell–activating reagent. In transcriptomic analyses, CAR T cells activated with Stim-R technology showed downregulation of exhaustion-associated gene sets and retained a unique subset of stem-like cells with effector-associated gene signatures following repeated exposure to tumor cells. Compared with the benchmark product, CAR T cells activated using the optimized Stim-R technology formulation exhibited higher peak expansion, prolonged persistence, and improved tumor control in a solid tumor xenograft model. Enhancing T-cell products with Stim-R technology during T-cell activation may help improve therapeutic efficacy against solid tumors.